Exagen Inc Stock Current Valuation
| XGN Stock | USD 3.88 0.19 5.15% |
Valuation analysis of Exagen Inc helps investors to measure Exagen's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Exagen's price fluctuation is very risky at this time. Calculation of the real value of Exagen Inc is based on 3 months time horizon. Increasing Exagen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Exagen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exagen Stock. However, Exagen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.88 | Real 3.99 | Hype 3.88 | Naive 4.42 |
The intrinsic value of Exagen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Exagen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Exagen Inc helps investors to forecast how Exagen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exagen more accurately as focusing exclusively on Exagen's fundamentals will not take into account other important factors: Exagen Inc Company Current Valuation Analysis
Exagen's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Exagen Current Valuation | 68.09 M |
Most of Exagen's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exagen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Exagen Inc has a Current Valuation of 68.09 M. This is 99.53% lower than that of the Biotechnology sector and 99.13% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.59% higher than that of the company.
Exagen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exagen's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics of similar companies.Exagen is currently under evaluation in current valuation category among its peers.
Exagen Fundamentals
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 68.09 M | ||||
| Shares Outstanding | 17.9 M | ||||
| Shares Owned By Insiders | 27.64 % | ||||
| Shares Owned By Institutions | 54.26 % | ||||
| Number Of Shares Shorted | 32.45 K | ||||
| Price To Book | 7.04 X | ||||
| Price To Sales | 1.19 X | ||||
| Revenue | 55.64 M | ||||
| Gross Profit | 33.11 M | ||||
| EBITDA | (11.14 M) | ||||
| Net Income | (15.12 M) | ||||
| Cash And Equivalents | 76.39 M | ||||
| Cash Per Share | 4.70 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.55 % | ||||
| Current Ratio | 9.30 X | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (13.28 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.83) X | ||||
| Target Price | 6.75 | ||||
| Number Of Employees | 209 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 66.04 M | ||||
| Total Asset | 44.69 M | ||||
| Retained Earnings | (294.33 M) | ||||
| Working Capital | 22.95 M | ||||
| Net Asset | 44.69 M |
About Exagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exagen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Exagen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.Moving against Exagen Stock
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Exagen Piotroski F Score and Exagen Altman Z Score analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.